Table 5.
Extent of statin exposure and changes in statin type or dose in the 6 months after the CPK measurement or rhabdomyolysis (for patients who were alive at month 6)
| Statin exposure afterwards | Normal CPK | One to two times ULN | Two to three times ULN | Three to four times ULN | >four times ULN | Rhabdomyolysis | Rhabdomyolysis/>10 times ULN |
|---|---|---|---|---|---|---|---|
| No statin | 8.6% | 12.9% | 26.0% | 35.9% | 44.9% | 58.0% | 55.9% |
| Same statin same dose | 82.7% | 75.6% | 60.5% | 48.1% | 38.8% | 34.0% | 31.9% |
| Same statin different dose | 2.4% | 3.8% | 5.0% | 6.5% | 3.9% | 2.0% | 1.9% |
| Different statin | 6.4% | 7.7% | 8.5% | 9.5% | 12.4% | 6.0% | 10.3% |
| Controls | Controls | Controls | Controls | Controls | Controls | Controls | |
|---|---|---|---|---|---|---|---|
| No statin | 10.3% | 5.1% | 4.0% | 3.8% | 3.5% | 2.9% | 4.5% |
| Same statin same dose | 86.5% | 91.5% | 92.7% | 93.1% | 92.6% | 94.9% | 91.7% |
| Same statin different dose | 0.8% | 0.8% | 0.7% | 0.7% | 1.1% | 1.0% | 1.7% |
| Different statin | 2.4% | 2.5% | 2.6% | 2.4% | 2.8% | 1.3% | 2.1% |